Evidence map›Paper›PMID 40614036›Full record

ReviewJournal of physiology and biochemistry2025

The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability.

Siarhei A Dabravolski, Vasily V Kashtalap, Ulyana V Rozhkova, Anastasia O Maksaeva, Vasily N Sukhorukov, Alexander N Orekhov

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Siarhei A DabravolskiDepartment of Biotechnology Engineering, Braude Academic College of Engineering, Snunit 51, P.O. Box 78, Karmiel, 2161002, Israel. sergedobrowolski@gmail.com.
Vasily V KashtalapResearch Institute for Complex Issues of Cardiovascular Diseases, 6 Barbarash Boulevard, Kemerovo, 650002, Russia.
Ulyana V RozhkovaInstitute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, Moscow, 125315, Russia.
Anastasia O MaksaevaInstitute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, Moscow, 125315, Russia.
Vasily N SukhorukovInstitute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, Moscow, 125315, Russia.
Alexander N OrekhovFaculty of Biology and Biotechnology, National Research University Higher School of Economics, 33, Profsoyuznaya Street, Building 4, Moscow, 117418, Russia.

Funding

Russian Science Foundation 25-25-00237
6 · The paper itself

Abstract

Atherosclerosis, a chronic inflammatory disease, involves a complex interplay between endothelial cells, smooth muscle cells, and inflammatory mediators. Cell-to-cell junctions, including adherens junctions (AJs), tight junctions (TJs), and gap junctions (GJs), play a critical role in maintaining vascular integrity and regulating cellular interactions in the vascular wall. This review summarises the molecular mechanisms by which these junctions contribute to atherosclerosis, focusing on key proteins like VE-cadherin (AJs), ZO-1, occludin, and claudins (TJs), and connexins (GJs). Dysregulation of these junctions, driven by factors such as oxidative stress, pro-inflammatory cytokines, atheroprone shear stress (aSS), and lipid-mediated signalling pathways, leads to endothelial dysfunction, increased permeability, monocyte infiltration, and plaque instability. Furthermore, the role of signalling pathways, including NFκB, PI3K/AKT, and Wnt/β-catenin, in the regulation of junctional proteins is explored. Emerging factors, including oxygenated cholesterol, radiation, and various drugs, provide new insights into junctional modulation in atherosclerosis. The potential of targeting junctional proteins and their associated pathways for therapeutic interventions is also discussed. Future studies focusing on the detailed mechanisms of junctional dysregulation in vivo and the clinical translation of these findings are necessary to develop novel therapeutic strategies for atherosclerosis. Clinical trial number Not applicable.

Indexed as

AtherosclerosisEndothelial CellsEndothelium, VascularInflammationIntercellular JunctionsPlaque, AtheroscleroticAdherens JunctionsAnimalsGap JunctionsHumansSignal TransductionTight JunctionsAdherens junctionsAtherosclerosisCardiovascular diseasesConnexinEndothelial dysfunctionInflammationTight junctionsVE-cadherin

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.